Clinical Significance of an HPV DNA Chip Test with Emphasis on HPV-16 and/or HPV-18 Detection in Korean Gynecological Patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Human papillomavirus (HPV) is a major risk factor for cervical cancer. Methods: We evaluated the clinical significance of the HPV DNA chip genotyping assay (MyHPV chip, Mygene Co.) compared with the Hybrid Capture 2 (HC2) chemiluminescent nucleic acid hybridization kit (Digene Corp.) in 867 patients. Results: The concordance rate between the MyHPV chip and HC2 was 79.4% (kappa coefficient, κ = 0.55). The sensitivity and specificity of both HPV tests were very similar (approximately 85% and 50%, respectively). The addition of HPV result (either MyHPV chip or HC2) to cytology improved the sensitivity (95%, each) but reduced the specificity (approximately 30%, each) compared with the HPV test or cytology alone. Based on the MyHPV chip results, the odds ratio (OR) for ≥ high-grade squamous intraepithelial lesions (HSILs) was 9.9 in the HPV-16/18 (+) group and 3.7 in the non-16/18 high-risk (HR)-HPV (+) group. Based on the HC2 results, the OR for ≥ HSILs was 5.9 in the HR-HPV (+) group. When considering only patients with cytological diagnoses of “negative for intraepithelial lesion or malignancy” and “atypical squamous cell or atypical glandular cell,” based on the MyHPV chip results, the ORs for ≥ HSILs were 6.8 and 11.7, respectively, in the HPV-16/18 (+) group. Conclusions: The sensitivity and specificity of the MyHPV chip test are similar to the HC2. Detecting HPV-16/18 with an HPV DNA chip test, which is commonly used in many Asian countries, is useful in assessing the risk of high-grade cervical lesions.
Abstract
Background: Human papillomavirus (HPV) is a major risk factor for cervical cancer. Methods: We evaluated the clinical significance of the HPV DNA chip genotyping assay (MyHPV chip, Mygene Co.) compared with the Hybrid Capture 2 (HC2) chemiluminescent nucleic acid hybridization kit (Digene Corp.) in 867 patients. Results: The concordance rate between the MyHPV chip and HC2 was 79.4% (kappa coefficient, κ = 0.55). The sensitivity and specificity of both HPV tests were very similar (approximately 85% and 50%, respectively). The addition of HPV result (either MyHPV chip or HC2) to cytology improved the sensitivity (95%, each) but reduced the specificity (approximately 30%, each) compared with the HPV test or cytology alone. Based on the MyHPV chip results, the odds ratio (OR) for ≥ high-grade squamous intraepithelial lesions (HSILs) was 9.9 in the HPV-16/18 (+) group and 3.7 in the non-16/18 high-risk (HR)-HPV (+) group. Based on the HC2 results, the OR for ≥ HSILs was 5.9 in the HR-HPV (+) group. When considering only patients with cytological diagnoses of “negative for intraepithelial lesion or malignancy” and “atypical squamous cell or atypical glandular cell,” based on the MyHPV chip results, the ORs for ≥ HSILs were 6.8 and 11.7, respectively, in the HPV-16/18 (+) group. Conclusions: The sensitivity and specificity of the MyHPV chip test are similar to the HC2. Detecting HPV-16/18 with an HPV DNA chip test, which is commonly used in many Asian countries, is useful in assessing the risk of high-grade cervical lesions.
참고문헌 (19)
- Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J Pathol, 189, pp.12~19 (1999)
- Castle PE, "Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities", J Natl Cancer Inst, 97, pp.1066~1071 (2005)
- Khan MJ, "The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice", J Natl Cancer Inst, 97, pp.1072~1079 (2005)
- Stoler MH, "High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study", Am J Clin Pathol, 135, pp.468~475 (2011)
- Wright TC Jr, "Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+cytology-negative results", Am J Clin Pathol, 136, pp.578~586 (2011)
- Bosch FX, "Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia", Vaccine, 26(Suppl 10), pp.K1~K16 (2008)
- de Sanjose S, "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study", Lancet Oncol, 11, pp.1048~1056 (2010)
- Saslow D, "American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer", Am J Clin Pathol, 137, pp.516~542 (2012)
- Solomon D, "The 2001 Bethesda System:terminology for reporting results of cervical cytology", JAMA, 287, pp.2114~2119 (2002)
- Terry G, "Detection of high-risk HPV types by the Hybrid Capture 2 test", J Med Virol, 65, pp.155~162 (2001)
- Muñoz N, "Epidemiologic classification of human papillomavirus types associated with cervical cancer", N Engl J Med, 348, pp.518~527 (2003)
- Huh WK, "Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance", Obstet Gynecol, 125, pp.330~337 (2015)
- 이재관, "Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition", Journal of Gynecologic Oncology, 24(2), pp.186~203 (2013), 대한부인종양학회
- Kang WD, "Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions", Int J Gynecol Cancer, 19, pp.924~928 (2009)
- Choi YD, "Detection of HPV genotypes in cervical lesions by the HPV DNA Chip and sequencing", Gynecol Oncol, 98, pp.369~375 (2005)
- Park S, "Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients", Diagn Microbiol Infect Dis, 76, pp.432~436 (2013)
- Brink AA, "HPV detection methods", Dis Markers, 23, pp.273~281 (2007)
- Um TH, "Comparison of HPV genotyping assays and Hybrid Capture 2 for detection of highrisk HPV in cervical specimens", Ann Clin Lab Sci, 41, pp.48~55 (2011)
- Cho EJ, "Evaluation of a liquid bead array system for high-risk human papillomavirus detection and genotyping in comparison with Hybrid Capture II, DNA chip and sequencing methods", J Med Microbiol, 60(Pt 2), pp.162~171 (2011)